Abstract:F-box and WD repeat domain containing 7 (FBXW7) is a substrate receptor of the ubiquitin ligase SKP1-Cullin1-F-box complex and a potent tumor suppressor that prevents unregulated cell growth and tumorigenesis. However, little is known about FBXW7-mediated control of cell metabolism and related functions in cancer therapy. Here, we report that FBXW7 expression inversely correlates with the expression levels of the key metabolic enzyme isocitrate dehydrogenase 1 (IDH1) in patients with glioma and public glioma datasets. Deletion of FBXW7 significantly increased both wild-type (WT) and mutant IDH1 expression, which was mediated by blocking degradation of sterol regulatory element binding protein 1 (SREBP1). The upregulation of neomorphic mutant IDH1 by FBXW7 deletion stimulated production of the oncometabolite 2-hydroxyglutarate at the expense of increasing pentose phosphate pathway activity and NADPH consumption, limiting the buffering ability against radiation-induced oxidative stress. In addition, FBXW7 knockout and IDH1 mutations induced nonhomologous end joining and homologous recombination defects, respectively. <i>In vitro</i> and <i>in vivo</i>, loss of FBXW7 dramatically enhanced the efficacy of radiation treatment in IDH1-mutant cancer cells. Taken together, this work identifies FBXW7 deficiency as a potential biomarker representing both DNA repair and metabolic vulnerabilities that sensitizes IDH1-mutant cancers to radiotherapy. SIGNIFICANCE: Deficiency of FBXW7 causes defects in DNA repair and disrupts NADPH homeostasis in IDH1-mutant glioma cells, conferring high sensitivity to radiotherapy.

FBXW7 Facilitates Nonhomologous End-Joining via K63-Linked Polyubiquitylation of XRCC4.

FBXW7 inactivation induces cellular senescence via accumulation of p53

FBXW7 Confers Radiation Survival by Targeting P53 for Degradation

The WD40 Domain of FBXW7 is a Poly(adp-Ribose)-binding Domain That Mediates the Early DNA Damage Response

Akt-Mediated Phosphorylation of XLF Impairs Non-Homologous End-Joining DNA Repair

Tumor Suppressor FBXW7 and Its Regulation of DNA Damage Response and Repair

FBXW7 tumor suppressor regulation by dualspecificity tyrosine-regulated kinase 2

Loss of FBXW7 Correlates with Increased IDH1 Expression in Glioma and Enhances IDH1-Mutant Cancer Cell Sensitivity to Radiation

Loss of FBXO31-mediated γH2AX foci formation impairs initiation of NHEJ and HR repair pathways, and sensitizes breast cancer to therapy

LARP7 is a BRCA1 Ubiquitinase Substrate and Regulates Genome Stability and Tumorigenesis

Chfr and RNF8 Synergistically Regulate ATM Activation

E3 ubiquitin ligase FBXW7 enhances radiosensitivity of non-small cell lung cancer cells by inhibiting SOX9 regulation of CDKN1A through ubiquitination

XLF Interacts with the XRCC4-DNA Ligase IV Complex to Promote DNA Nonhomologous End-Joining

FBXW7 in Cancer: What Has Been Unraveled Thus Far?

Clinical significance of FBXW7 loss of function in human cancers

LRF Maintains Genome Integrity by Regulating the Non-Homologous End Joining Pathway of DNA Repair

Interactome analysis identifies a new paralogue of XRCC4 in non-homologous end joining DNA repair pathway

FBXW7 attenuates tumor drug resistance and enhances the efficacy of immunotherapy

Molecular insights and clinical implications for the tumor suppressor role of SCFFBXW7 E3 ubiquitin ligase

Ubiquitylation of Rad51d Mediated by E3 Ligase Rnf138 Promotes the Homologous Recombination Repair Pathway.

UHRF1 Mediated Ubiquitination of Non-Homologous End Joining Factor XLF Promotes DNA Repair in Human Tumor Cells